Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00054818" target="_blank" >RIV/00216224:14110/11:00054818 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3109/10428194.2011.578312" target="_blank" >http://dx.doi.org/10.3109/10428194.2011.578312</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2011.578312" target="_blank" >10.3109/10428194.2011.578312</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late

Popis výsledku v původním jazyce

Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 x 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 x 10(6) CD34+ cells/kg. Patients to whom plerixaforwas administered late (&gt;= 15 days) after chemotherapy, after a long duration (&gt;= 13 days) of treatment with G-CSF, or when the white blood cell count was high (&gt;= 20 x 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was shown to rescue mobilizations at a comparable rate in patients with critically low levels of peripheral blood CD34+ cells (53/mL) and those with higher concentrations.

Název v anglickém jazyce

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late

Popis výsledku anglicky

Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 x 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 x 10(6) CD34+ cells/kg. Patients to whom plerixaforwas administered late (&gt;= 15 days) after chemotherapy, after a long duration (&gt;= 13 days) of treatment with G-CSF, or when the white blood cell count was high (&gt;= 20 x 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was shown to rescue mobilizations at a comparable rate in patients with critically low levels of peripheral blood CD34+ cells (53/mL) and those with higher concentrations.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia & Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

1711-1719

Kód UT WoS článku

000294228100016

EID výsledku v databázi Scopus

—